Cortical GABA, Striatal Dopamine and Midbrain Serotonin as the Key Players in Compulsive and Anxiety Disorders - Results from In Vivo Imaging Studies

Various factors are discussed in the pathophysiology of anxiety disorders, including dysfunctions of the (DA)ergic, serotonin (5-HT)ergic and GABAergic system. We assessed the contribution of the individual synaptic constituents by subjecting all available in vivo imaging studies on patients with anxiety disorders to a retrospective analysis. On a total of 504 patients with obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorder (PD), phobia, or posttraumatic stress-disorder (PTSD) and 593 controls, investigations of VMAT2, DAT, SERT, D1, D2, 5-HTIA, 5-HT2A, GABA(A), and NK1 receptor binding in neostriatum, ventral striatum, thalamus, neocortex, limbic system, cingulate, midbrain/ pons or cerebellum were performed using either PET or SPECT. Separate analyses of the individual disorders showed significant decreases of striatal D2 receptors in OCD (-18%), mesencephalic SERT in OCD (-13%), frontocortical GABAA receptors in PD (-13%) and temporocortical GABAA receptors in GAD (-16%). Pooling of all disorders yielded a significant reduction of mesencephalic SERT (-13%), mesencephalic (-27%) as well as cingulate 5-HT1A receptors (-18%), striatal D2 receptors (-21%) and frontal (-14%), temporal (-14%), occipital (-13%) and cingulate GABAA receptors (-15%). The results show that DA, 5-HT, and GABA play a major role in all subtypes of anxiety disorders. In particular, the findings imply that the regulation state of DA as modulated by GABA and 5-HT may be crucial for the development of anxiety- and compulsion-related disorders. As GABA and 5-HT inhibit DAergic neurotransmission, the reductions of GABAA, 5-HT1A and SERT can be assumed to result in an enhanced activity of the mesolimbic DAergic system. This notion is also reflected by the decrease of striatal D2 receptor binding, which is indicative of an increased availability of synaptic DA.

[1]  A. Grace,et al.  Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticulata inhibitory neurons. , 1979, European journal of pharmacology.

[2]  J. Girault,et al.  In vivo release of [3H]γ-aminobutyric acid in the rat neostriatum—II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen , 1986, Neuroscience.

[3]  W. Kaschka,et al.  Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. , 1995, Journal of psychiatric research.

[4]  A. Pitkänen,et al.  Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder , 1995, Nuclear medicine communications.

[5]  J. Tiihonen,et al.  Dopamine reuptake site densities in patients with social phobia. , 1997, The American journal of psychiatry.

[6]  J. Tiihonen,et al.  Seasonal variation in the occurrence of homicide in Finland. , 1997, The American journal of psychiatry.

[7]  M. Mikuni,et al.  Alterations of benzodiazepine receptor binding potential in anxiety and somatoform disorders measured by 123I-iomazenil SPECT. , 1997, Radiation medicine.

[8]  J. Karhu,et al.  Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis , 1997, Molecular Psychiatry.

[9]  V J Cunningham,et al.  Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. , 1998, Archives of general psychiatry.

[10]  C. Brandt,et al.  Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder , 1998, Journal of Neural Transmission.

[11]  L. Barré,et al.  Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study , 1999, The European journal of neuroscience.

[12]  R. Albin,et al.  Striatal presynaptic monoaminergic vesicles are not increased in Tourette’s syndrome , 1999, Neurology.

[13]  J. Huston,et al.  The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. , 1999, Neuroreport.

[14]  J. Huston,et al.  Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P , 2000, Neuroscience Letters.

[15]  S. Southwick,et al.  Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. , 2000, The American journal of psychiatry.

[16]  David Silbersweig,et al.  SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder , 2000, Biological Psychiatry.

[17]  R. Schwarting,et al.  Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery , 2000, Neuropeptides.

[18]  M. Liebowitz,et al.  Low dopamine D(2) receptor binding potential in social phobia. , 2000, The American journal of psychiatry.

[19]  M. Carlsson On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  H. Westenberg,et al.  Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. , 2002, The Journal of clinical psychiatry.

[21]  D. Stein,et al.  Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. , 2002, The Journal of clinical psychiatry.

[22]  Mark Slifstein,et al.  Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652 , 2003, Biological Psychiatry.

[23]  J. Marksteiner,et al.  Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites. , 2004, Pharmacopsychiatry.

[24]  R. Lydiard The role of GABA in anxiety disorders. , 2003, The Journal of clinical psychiatry.

[25]  Y. Ryu,et al.  Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  H. Möller,et al.  Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder , 2003, Biological Psychiatry.

[27]  Peter Herscovitch,et al.  Reduced Serotonin Type 1A Receptor Binding in Panic Disorder , 2004, The Journal of Neuroscience.

[28]  U. Müller,et al.  Reduced serotonin transporter–availability in obsessive–compulsive disorder (OCD) , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[29]  N. V. D. Van der Wee,et al.  Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. , 2004, The American journal of psychiatry.

[30]  J. Tiihonen,et al.  SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[31]  H. Westenberg,et al.  Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder , 2004, Biological Psychiatry.

[32]  J. Tiihonen,et al.  Reduced brain serotonin transporter binding in patients with panic disorder , 2004, Psychiatry Research: Neuroimaging.

[33]  A. Bockisch,et al.  Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[34]  Claus Svarer,et al.  Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. , 2005, The international journal of neuropsychopharmacology.

[35]  W. Drevets,et al.  No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. , 2005, The American journal of psychiatry.

[36]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[37]  Thomas Villmann,et al.  Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder , 2005, Psychiatry Research: Neuroimaging.

[38]  H. Emrich,et al.  Serotonin transporter binding in Tourette Syndrome , 2005, Neuroscience Letters.

[39]  S. Fromm,et al.  Serotonin Transporter Binding in Bipolar Disorder Assessed using ( 11 C)DASB and Positron , 2006 .

[40]  U. Müller,et al.  Serotonin Transporter Imaging with [123I]β-CIT SPECT before and after One Year of Citalopram Treatment of Obsessive-Compulsive Disorder , 2006, Neuropsychobiology.

[41]  Masanori Ichise,et al.  Serotonin Transporter Binding in Bipolar Disorder Assessed using [11C]DASB and Positron Emission Tomography , 2006, Biological Psychiatry.

[42]  Wolfgang Wadsak,et al.  Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder , 2007, Biological Psychiatry.

[43]  T. Poeppel,et al.  Investigating the Dopaminergic Synapse In Vivo. I. Molecular Imaging Studies in Humans , 2007, Reviews in the neurosciences.

[44]  D. Perani,et al.  Fluvoxamine Treatment and D2 Receptors: a Pet Study on OCD Drug-Naïve Patients , 2007, Neuropsychopharmacology.

[45]  T. Bolwig,et al.  Reduced midbrain‐pons serotonin transporter binding in patients with obsessive–compulsive disorder , 2007, Acta psychiatrica Scandinavica.

[46]  Kurt Hornik,et al.  [123I]-β-CIT SPECT Imaging Shows Reduced Thalamus–Hypothalamus Serotonin Transporter Availability in 24 Drug-Free Obsessive-Compulsive Checkers , 2007, Neuropsychopharmacology.

[47]  A. Heinz,et al.  Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity – a [11C]DASB PET study , 2007, Journal of Neural Transmission.

[48]  E. Pehek,et al.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. , 2007, Pharmacology & therapeutics.

[49]  D. Nutt,et al.  Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. , 2008, The British journal of psychiatry : the journal of mental science.

[50]  M. Liebowitz,et al.  Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings , 2008, Depression and anxiety.

[51]  R. Boellaard,et al.  Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder , 2008, Molecular Psychiatry.

[52]  D. Nutt,et al.  Serotonin 5-HT 1 A receptor binding in people with panic disorder : positron emission tomography study , 2008 .

[53]  Dan J Stein Psychobiology of Anxiety Disorders and Obsessive-Compulsive Spectrum Disorders , 2008, CNS Spectrums.

[54]  H. Westenberg,et al.  Increased Serotonin and Dopamine Transporter Binding in Psychotropic Medication–Naïve Patients with Generalized Social Anxiety Disorder Shown by 123I-β-(4-Iodophenyl)-Tropane SPECT , 2008, Journal of Nuclear Medicine.

[55]  W. Drevets,et al.  Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. , 2008, Archives of general psychiatry.

[56]  Alessandra Gorini,et al.  In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder , 2008, NeuroImage.

[57]  Albert Gjedde,et al.  Mechanisms of Dopaminergic and Serotonergic Neurotransmission in Tourette Syndrome: Clues from an In Vivo Neurochemistry Study with PET , 2008, Neuropsychopharmacology.

[58]  M. Liebowitz,et al.  Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder , 2009, Depression and anxiety.

[59]  C. Antke,et al.  In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders , 2009, Behavioural Brain Research.

[60]  W. Drevets,et al.  Decreased Neurokinin-1 (Substance P) Receptor Binding in Patients with Panic Disorder: Positron Emission Tomographic Study with [18F]SPA-RQ , 2009, Biological Psychiatry.

[61]  Trevor R. Norman,et al.  Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. , 2009, Journal of affective disorders.